When Treatment Is Not Appropriate
By Kyle Kingsley, MD | Medical Director, LiteWell
The most important decision a physician makes is often not how to treat, but whether to treat at all. In hormone health, metabolic medicine, and longevity care — fields where demand is high and access is easy — the willingness to say “not yet,” “not this,” or “not for you” is a defining marker of medical quality.
At LiteWell, declining or deferring treatment is not a failure of care. It is care. This article explains how we think about the situations in which starting, continuing, or intensifying therapy is not in a patient’s best interest — and why that discipline protects you.
Why “no” is a clinical skill
A prescription is a medical intervention with real biological consequences. The same rigor that justifies starting a therapy must justify not starting one. Guideline-issuing bodies — including the Endocrine Society and the American Urological Association for testosterone therapy, and The Menopause Society and ACOG for menopausal hormone therapy — frame every treatment decision as a benefit-versus-risk judgment for a specific person, not a default response to a lab value or a symptom checklist.
That means two patients with identical numbers can, appropriately, receive different recommendations. The evaluation, not the request, drives the decision.
Situations where treatment may not be appropriate
The categories below are illustrative of how we reason, not an exhaustive list. Every case is individualized.
1. Absolute contraindications
Some conditions make a given therapy unsafe regardless of how much a patient wants it. Examples include active or recently treated hormone-sensitive cancers before appropriate clearance, untreated severe sleep apnea or uncontrolled erythrocytosis in the context of testosterone therapy, certain thromboembolic or cardiovascular histories for systemic hormone therapy, and pregnancy or the possibility of pregnancy for many metabolic and hormonal agents. In these cases, the answer is a clear no, with an explanation and — where possible — an alternative.
2. The diagnosis has not been established
Symptoms like fatigue, low libido, weight gain, or brain fog are real, but they are also nonspecific. They can stem from thyroid disease, depression, anemia, sleep disorders, medication effects, or lifestyle factors that no hormone or metabolic drug will fix. Treating a presumed diagnosis before confirming it can mask a more serious or more treatable problem. When the workup is incomplete, the appropriate step is to finish the evaluation — see our companion piece on Clinical Evaluation Standards].
3. A reversible cause should be addressed first
Low testosterone driven by obesity, poor sleep, or overtraining; menstrual or metabolic disruption driven by undernutrition or extreme stress; elevated glucose that responds to nutrition and activity — these often improve when the root cause is treated. Reaching for a prescription before addressing a reversible contributor can produce a lifelong dependence on a therapy that may not have been necessary.
4. The risk-benefit balance does not favor treatment
Even when a therapy is available and a patient qualifies on paper, the expected benefit may be small and the risk meaningful — particularly at older ages, with significant comorbidity, or when the symptom burden is mild. Shared decision-making means we lay out that balance honestly rather than treating simply because we can.
5. Monitoring or follow-up cannot be assured
Therapies that require ongoing surveillance — testosterone, systemic hormone therapy, GLP-1 and other metabolic agents — are only as safe as the monitoring behind them. If a patient cannot or will not participate in follow-up labs and visits, continuing therapy may be unsafe. See Monitoring Protocols].
6. When continuing is no longer appropriate — deprescribing
Stopping is a clinical decision too. If a therapy is not producing benefit, is causing side effects that outweigh its value, or is no longer indicated as a patient’s health changes, the right move is to taper or discontinue. Good medicine reassesses; it does not simply refill.
What we do instead of prescribing
Declining a specific therapy is rarely the end of the conversation. Depending on the situation, an appropriate plan may include completing diagnostic testing, treating an underlying condition, addressing sleep, nutrition, activity, and alcohol, referring to a specialist, or re-evaluating on a defined timeline. The goal is always the patient’s health outcome — not the transaction.
Key takeaways
- Deciding *not* to treat is a core part of responsible care, not a denial of it.
- Absolute contraindications, an unconfirmed diagnosis, reversible causes, an unfavorable risk-benefit balance, and the inability to monitor are all valid reasons to withhold or defer therapy.
- Two patients with the same labs can appropriately receive different recommendations, because the evaluation drives the decision.
- Stopping a therapy that is no longer helping is as much a medical decision as starting one.
Frequently asked questions
If my labs are abnormal, why might you still not treat?
A number outside a reference range is data, not a diagnosis. We treat people, not values — and only after confirming that therapy is likely to help more than it could harm.
Does declining treatment mean you can’t help me?
No. It usually means the most helpful next step is more evaluation or a different intervention. We will always explain the reasoning and the alternative.
Can I get a second opinion?
Absolutely. We encourage it. A physician confident in a recommendation welcomes scrutiny.
Sources and further reading
Our approach is grounded in current clinical practice guidance from the Endocrine Society, the American Urological Association (AUA), The Menopause Society, the American College of Obstetricians and Gynecologists (ACOG), the American Association of Clinical Endocrinology (AACE), and U.S. Food and Drug Administration labeling. [Reviewing physician to attach specific guideline citations and links.]
This article is for general educational purposes and does not constitute medical advice or establish a physician-patient relationship. Individual treatment decisions require a personal evaluation by a licensed clinician.
Related reading: [Clinical Evaluation Standards] · [Monitoring Protocols] · [Medication Safety Practices]
